JPRN-jRCT2031210338招募中1 期
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Ishibashi Hideyasu0 个研究点目标入组 184 人开始时间: 2021年9月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Adults 20 years of age or older;
- •-Female participants of childbearing potential must agree to use a highly effective form of contraception;
- •-Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy;
- •-Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists;
- •-Measurable disease per RECIST 1.1
- •-Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1
- •-Life expectancy of at least 12 weeks.
- •-Adequate organ function as determined by laboratory assessments.
- •-Adequate cardiac ejection fraction as measured by echocardiogram.
- •-Arm A, D, E ,F and G -Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese.
- •-Arm D, E, F and G only: has been deemed suitable for assigned treatment based on assessment by the investigator.
排除标准
- •Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter.
- •-Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.
- •-Toxicity from previous anticancer treatment, including; greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved.
- •-Known additional malignancy that progressed or required active treatment within the last 2 years.
- •-Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •-Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years.
- •-Concurrent medical condition requiring the use of systemic immunosuppressive treatment.
- •-Cirrhosis or current unstable liver or biliary disease per investigator assessment.
- •-Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- •-Prolonged QT corrected for heart rate according to Fridericia's formula as measured by electrocardiogram.
- •-History of hypersensitivity to monoclonal antibodies. For combination therapy, history of hypersensitivity to dostarlimab or its excipients.
- •-History or evidence of significant cardiovascular (CV) risk.
- •-Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.
- •-History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required steroids, or evidence of active, noninfectious pneumonitis.
- •-Pregnant or lactating woman.
- •-Receipt of live vaccine within 30 days of the start of study intervention.
- •-Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention.
- •-Major surgery less than 4 weeks before the first dose of study intervention.
- •-Known drug or alcohol abuse.
研究者
相似试验
招募中
1 期
Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered to Participants with Advanced Solid TumorsSelected Advanced Solid TumorsJPRN-jRCT2031220403Ishibashi Hideyasu126
进行中（未招募）
1 期
A Study of JNJ-67856633 in Participants with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaJPRN-jRCT2041200066Fujikawa Ei300
已完成
不适用
A phase I/IIa open-label First-in-Human study to assess safety and pharmacokinetics and explore biomarker effects of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in subjects with cutaneous warts.cutaneous warts10014982NL-OMON41213Cutanea Life Sciences12
进行中（未招募）
不适用
A study in volunteers with cutaneous warts to assess safety and the effect of the body on topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide.Cutaneous wartsMedDRA version: 16.1Level: HLTClassification code 10033724Term: Papilloma viral infectionsSystem Organ Class: 100000004862EUCTR2013-005569-38-NLCutanea Life Sciences
暂停
1 期
Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumorsadvanced solid tumorsJPRN-jRCT2031220077Ishibashi Hideyasu300